PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molvisLink to Publisher's site
 
Mol Vis. 2010; 16: 1823–1831.
Published online 2010 September 4.
PMCID: PMC2956661

Transport of L-carnitine in human corneal and conjunctival epithelial cells

Abstract

Purpose

Previously we demonstrated expression and localization of carnitine/organic cation transporters, OCTN1 and OCTN2, in human corneal and conjunctival epithelia. The present study aimed to examine the characteristics of L-carnitine transporters in cultured human limbal corneal (HCLE) and conjunctival epithelial (HCjE) cells.

Methods

Time-course, Na+-dependence, kinetics, energy- and pH- dependence of L-carnitine transport were investigated by monitoring L-[3H]carnitine uptake into HCLE and HCjE cells. To determine the specificity of action, competition and inhibition studies were performed.

Results

The uptake of L-carnitine into HCLE and HCjE cells was saturable and time-dependent. An Eadie-Hofstee plot showed two distinct components: a high- and a low- affinity carnitine transport system in HCLE and/or HCjE cells. L-carnitine transport was significantly inhibited by the metabolic inhibitors (sodium azide, dinitrophenol, iodoacetic acid). The L-carnitine analogs (D-carnitine, acetyl-L-carnitine and γ-butyrobetaine), tetraethylammonium (TEA), 2-amino-2-norbornane carboxylic acid (BCH), strongly inhibited uptake of L-[3H]carnitine. Uptake of L-[3H]carnitine also required the presence of Na+ in the external medium and the uptake activity was maximal at pH 5.5. The anti-OCTN2 antibody blocked L-carnitine uptake in both HCLE and HCjE cells whereas the anti-OCTN1 antibody did not significantly block L-carnitine uptake.

Conclusions

L-carnitine is transported into HCLE and HCjE cells by an active carrier mediated transport system that is time-, Na+-, energy- and pH- dependent. The carnitine/organic cation transporter OCTN2 appears to play a dominant role in this process.

Introduction

Dry eye syndrome (DES) can result in epithelial desiccation and ocular surface irritation. These symptoms can greatly affect the quality of life for affected patients. One of the key factors in dry eye is an increase in tear osmolarity. This increase in osmolarity can adversely affect cells causing cell shrinkage and eventual death. To compensate for hypertonic conditions, several compatible solutes have been incorporated into topical formulations for the treatment and management of dry eye syndrome. These are organic compounds that work like electrolytes to balance osmotic pressure, yet do not interfere with cellular metabolism, thus aiding survival of organisms under extreme osmotic stress. L-carnitine is one such compatible solute, due to its documented osmoregulatory activities [1]. L-carnitine has been demonstrated as an osmoprotectant against hyperosmotic stress of corneal epithelial cells in vitro [2,3]. Further, the topical use of L-carnitine has been demonstrated to result in rapid and consistent improvements in the signs and symptoms of dry eye patients [4]. These observations suggest that L-carnitine may play a homeostatic role in the eye, in addition to its well known role in β-oxidation of fatty acids by facilitation of transport of long-chain fatty acids into the mitochondria as acylcarnitine esters [5,6]. This is consistent with the findings of others who have demonstrated lower carnitine levels in patients with dry eye syndrome than in healthy subjects [7]. Pescosolido and colleagues [7] speculated that an imbalance in the concentration of carnitine molecules in the tear film may be partially responsible for the damage to ocular cells exposed to the hypertonic tear film found in dry eye syndrome.

Topically applied L-carnitine is actively taken up by ocular cells in animal models [8,9]. Further evidence suggests the existence of a carrier-mediated organic cation transport process in the rabbit conjunctiva that mediates absorption of organic amines, although the underlying mechanisms have yet to be fully elucidated [8,9]. Previously, we have reported the presence of organic cation/carnitine transporters, OCTN1 and OCTN2, in human corneal and conjunctival epithelial cells, as well as rabbit corneal and conjunctival epithelium [10]. We have further demonstrated that OCTN1 and OCTN2 are predominately localized in the apical membrane of these cells [10]. However, the mechanism of facilitation of carnitine transport in corneal and conjunctival epithelium requires clarification.

Together with the organic cation and organic anion transporters (OCTs and OATs), the OCTN transporters (organic cation transporter novel type) belong to the SLC22A family within the solute carrier (SLC) superfamily [11]. The organic cation transporter (OCTN) subfamily comprises three members; OCTN1, OCTN2, and OCTN3 that transport the organic cations, L-carnitine, and acylcarnitines [12], differing in their affinity and capacity for compound transport, energization of transport, and sensitivity to inhibitors [11,13-16]. OCTN1 (SLC22A4) has been functionally demonstrated as a multispecific, bidirectional, and pH-dependent organic cation transporter, presumably energized by a proton antiport mechanism that transports L-carnitine in a Na+-dependent manner [17,18]. OCTN2 (SLC22A5) is unique in that it transports carnitine with high affinity in a Na+-dependent manner and transports organic cations in a Na+-independent manner [15,19]. The OCTN2 carnitine-specific transport system has been documented in human kidney, skeletal muscle, heart, and placenta [14,20]. OCTN3 (SLC22A21) meditates L-carnitine transport in a Na+-independent manner and has higher affinity for L-carnitine than OCTN1 or OCTN2 [17]. In addition, L-carnitine can also be transported by the CT2 (human carnitine transporter, SLC22A16) [21] and by ATBo,+ (amino acid transporter B0,+, SLC6A14) [22], which are Na+-independent and Na+-dependent transporters respectively. ATBo,+ is reported to be a low-affinity transporter for L-carnitine [22].

To further our previous investigation in which we demonstrated the expression of L-carnitine transport proteins in corneal and conjunctival epithelium [10], the present study extends the functional characterization of L-carnitine transporters through examination of the sodium-, energy- and pH-dependence, and substrate specificity of the transport process.

Methods

Materials

Cell culture media (keratinocyte serum-free medium, K-SFM), media supplements, and epidermal growth factor (EGF) were purchased from Invitrogen-Gibco (Grand Island, NY). L-carnitine, D-carnitine, acetyl-L-carnitine, tetraethylammonium (TEA), 2-amino-2-norbornane carboxylic acid (BCH), γ-butyrobetaine, sodium azide, dinitrophenol, iodoacetic acid, and Triton X-100 were from Sigma Chemical Co. (St Louis, MO). L-[methyl-3H]carnitine hydrochloride (specific activity of 3.07 TBq/mmol) was obtained from GE Healthcare UK Limited, Amersham Place, Little Chalfont (Buckinghamshire, UK). Goat anti-human OCTN1 polyclonal antibody and goat anti-human OCTN2 polyclonal antibody were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All other reagents were of analytical grade.

Cell culture

Immortalized human corneal-limbal epithelial (HCLE) and human conjunctival epithelial (HCjE) cell lines derived from primary cultures of HCLE and HCjE cells (a kind gift from Ilene Gipson’s laboratory, Schepens Eye Research Institute, Boston, MA) were used. HCLE and HCjE cells were cultured as described previously [23,24]. Briefly, cells were maintained on plastic at 2×104/cm2 in K-SFM, supplemented with 25 μg/ml bovine pituitary extract, 0.2 ng/ml EGF and 0.4 mM CaCl2 and were grown at 37 °C in a 5% carbon dioxide atmosphere. To enhance nutrient composition, the cultures were switched at approximately 50% confluence to a 1:1 mixture of K-SFM and low calcium DMEM/F12 (Invitrogen) to achieve confluence.

Transport study

HCLE and HCjE cells were grown on 24-well tissue culture plates at an initial seeding density of 5×105 cells/well to 80%–90% confluence. Following the removal of media, the cells were pre-incubated with uptake buffer (25 mM Tris/HEPES, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, and 5 mM glucose, pH 7.4) at 37 °C in air for 60 min. L-[3H] carnitine (L-[methyl-3H]carnitine hydrochloride) was added to the medium in the presence or absence of unlabeled substrates of varying concentrations. Non-specific uptake for the labeled substrates was determined using 100 fold excess unlabeled L-carnitine (up to 10 mM due to solubility). To obtain the specific uptake, the nonspecific uptake values were subtracted from the total uptake values. At a given incubation time, the incubation medium was removed, and the cells were rinsed three times in ice-cold PBS for 30 s each. The cell membranes were then solubilized using 0.1 M NaOH and 0.1% Triton X-100, and aliquots were removed for liquid scintillation counting (disintegrations/min). The cellular protein content was measured using a LavaPep peptide quantification kit (Fluorotechnics Pty Limited, Sydney, Australia) with a BSA standard. For Na+-free experiments, NaCl was substituted with equimolar choline chloride in the above buffer [17].

The energy-dependence of L-[3H]carnitine uptake was investigated by pre-treating the cells with metabolic inhibitors, sodium azide (10 mM), dinitrophenol (10 mM), or iodoacetic acid (10 mM) for 30 min followed by incubation with 24 nM L-[3H]carnitine for 30 min.

To study the pH-dependence of the L-[3H]carnitine uptake, cells were pre-incubated for 60 min in the uptake buffer at pH 5.5, 6.5, 7.4, and 8.5, respectively. L-[3H]carnitine (24 nM) was then added and incubation was continued for 30 min.

Substrate specificity was examined by pre-incubating cells for 60 min in the uptake buffer followed by further incubation of cells for 30 min with L-[3H]carnitine (24 nM) in the absence (control) or presence of 0.5 and 1.0 mM of L-carnitine structural analogs (unlabeled L-carnitine, D-carnitine, acetyl-L-carnitine, or γ-butyrobetaine), or 0.1 and 1.0 mM tetraethylammonium (TEA, a known organic cation substrate for OCTN2) [25], and 0.1 and 1.0 mM 2-amino-2-norbornane carboxylic acid (BCH, a known specific inhibitor for ATB0,+) [22].

For blocking experiments, cells were pre-incubated for 60 min with uptake buffer in the absence (control) or presence of OCTN1 (1:500) and/or OCTN2 (1:500) antibody at 37 °C; L-[3H]carnitine (24 nM) was then added and the incubation was continued for 30 min.

mRNA expression

mRNA expression was investigated as previously reported [10]. Briefly, total RNA was extracted from cultured HCLE and HCjE cells using the SV Total RNA Isolation System (Promega, Madison, WI). RT–PCR was performed using SuperScript One-step RT–PCR with Platinum Taq System (Invitrogen). Purity and integrity of RNA was verified using an ultraviolet spectrophotometer and agarose gel visualization of ribosomal bands, respectively. Transcripts for ATB0,+ were amplified using the primers described in Table1. The transcripts for OCTN1 or OCTN2 were amplified as previously reported [10] using the primers listed in Table 1. A control housekeeping gene β-actin (ACTB) was amplified under the same conditions [10]. The PCR products were separated by electrophoresis on a 1.2% agarose gel and analyzed by Gel-Pro analyzer version 3.1 software (Media Cybernetics, Silver Spring, MD). The ratio of integrated density of target genes over ACTB was used to normalize the relative mRNA expression. The PCR products were purified using Wizard SV Gel and PCR Clean-up System (Promega). The identity of each PCR product was verified by DNA sequencing (Department of Biologic Sciences, Macquarie University DNA Analysis Facility, Sydney, Australia).

Table 1
Primer sequences.

Data analysis

The uptake experiments were routinely executed in duplicate and each experiment was repeated three to four times. The results are expressed as mean ±SD. The apparent kinetic parameters, Km and the maximal transport rate (Vmax), of carnitine uptake by HCLE and HCjE cells were estimated by nonlinear regression curve fitting according to the following Michaelis–Menten type equation with two saturable transport components, where v and [s] are the velocity of substrate uptake and the substrate concentration respectively and indices 1 and 2 indicate the high- and low-affinity components respectively;

v=Vmax1 × [s]/(Km1+[s])+Vmax2 × [s]/(Km2+[s])

The Km and V max values were determined from Lineweaver-Burk plots. Student’s unpaired t -test was performed using commercial computer software (SPSS; SPSS Inc., Chicago, IL). Post hoc multiple comparisons were analyzed incorporating the Bonferroni correction. Statistical significance was set at p<0.05.

Results

Time course and Na+ dependence of L-[3H] carnitine uptake by HCLE and HCjE cells

L-[3H] carnitine uptake in both HCLE (Figure 1A) and HCjE (Figure 1B) cells increased in a time-dependent manner, and appeared to be linear up to at least 90 min. When Na+ in the uptake buffer was replaced with choline, the uptake was decreased by 90% (p=0.001). Consequently, subsequent experiments were performed using an uptake period of 30 min in the presence of Na+.

Figure 1
Time course and Na+-dependence of L-carnitine uptake. The uptake of 12nM L-[3H]carnitine by HCLE (A) or HCjE (B) cells was measured at pH 7.4 and 37 °C in the presence or absence of Na+. For Na+-free buffer, NaCl was replaced by an equimolar concentration ...

Kinetics of L-[3H]carnitine uptake in HCLE or HCjE cells

Carnitine uptake by HCLE or HCjE cells was concentration-dependent and the uptake appeared to be saturable (Figure 2A). The kinetics of L-[3H]carnitine uptake in HCLE and HCjE cells were analyzed by fitting the data to the Michaelis–Menten models using nonlinear regression analysis. The Eadie-Hofstee plot in which the uptake rate (v) was plotted as a function of the uptake rate/carnitine concentration ratio (v/s) clearly indicated two distinct components: a high-affinity and a low-affinity carnitine transport system in both HCLE (Figure 2B) and HCjE (Figure 2C) cells. The kinetic analysis yielded apparent Michaelis–Menten constants (Km) of 9.48±2.7 µM and 363.64±34.4 µM for high- and low-affinity carnitine transport, respectively, in HCLE cells (Table 2), and 9.39±1.3 µM and 196.03±17.1 µM for high- and low- affinity transport, respectively, in HCjE cells (Table 2). The maximum transport activities (Vmax) of 0.48±0.09 pmol/h/mg protein (high affinity) and 5.1±0.3 pmol/h/mg protein (low affinity) were estimated for HCLE, and 0.36±0.07 pmol/h/mg protein (high affinity) and 1.99±0.2 pmol/h/mg protein (low affinity) for HCjE (Table 2). These results suggest the existence of both high- and low- affinity L-carnitine transport systems in HCLE and HCjE cells.

Figure 2
Concentration dependence and the kinetic characteristics of L-carnitine uptake.   A: Concentration dependence of carnitine uptake by HCLE or HCjE cells; B and C:  the kinetic characteristics of L-[3H]carnitine uptake with the Eadie–Hofstee ...
Table 2
Determination of Km and Vmax of L-[3H]carnitine uptake in HCLE or HCjE cells at pH 7.4 and 37 °C.

Energy-dependence of L-[3H]carnitine uptake by HCLE and HCjE cells

Following pretreatment with metabolic inhibitors sodium azide, dinitrophenol, or iodoacetic acid for 30 min, the uptake of L-[3H]carnitine was reduced to approximately 80%, 70%, and 30%, respectively (p<0.01), for both HCLE and HCjE cells (Table 3).

Table 3
Energy-dependence of the uptake of L-[3H]carnitine by HCLE or HCjE cells at pH 7.5 and 37 °C.

pH - dependence of the uptake of L-[3H]carnitine by HCLE and HCjE cells

Figure 3 shows the uptake of 24 nM L-[3H]carnitine by HCLE or HCjE cells in the external uptake buffer at pH 5.5, 6.5, 7.4, or 8.5. The uptake activity was highest at pH 5.5 (p=0.005 and p=0.002 for HCLE and HCjE cells, respectively). The activity was higher at pH 6.5 than pH 7.4 (p=0.002 and p=0.007 for HCLE and HCjE cells, respectively), but no difference was found at pH 7.4 compared to pH 8.5. No changes in cell morphology were observed at pH 5.5 and pH 6.5 (data not shown).

Figure 3
Effect of the pH of the medium on the uptake of L-[3H]carnitine by HCLE or HCjE cells at 37 °C. HCLE or HCjE cells were pre-incubated for 60 min in uptake buffer of different pH values at 37 °C; L-[3H]carnitine (24 nM) ...

Structural analog, organic cation and BCH inhibition on the uptake of L-[3H]carnitine by HCLE and HCjE cells

As shown in Table 4, the structural analogs L-carnitine, D-carnitine, acetyl-L-carnitine and γ-butyrobetaine significantly inhibited the uptake of L-[3H]carnitine by both HCLE and HCjE cells. For both cell types, the inhibitory effect of L-carnitine was slightly greater than that of D-carnitine and acetyl-L-carnitine, and the effect of γ-butyrobetaine, a precursor of carnitine biosynthesis, was approximately equal to that of L-carnitine. No difference was found between D-carnitine and acetyl-L-carnitine. Inhibition was also concentration dependent. TEA, a known organic cation transported by OCTN2 [25], and BCH, a known specific inhibitor for ATB0,+ [22], both significantly inhibited L-[3H]carnitine uptake by HCLE and HCjE cells in a concentration dependent manner (Table 4).

Table 4
Inhibitory effect of structural analogs, organic cation and BCH on the uptake of L-[3H]carnitine by HCLE or HCjE cells.

mRNA expression of ATB0,+

The expression of OCTN1 and OCTN2 has been reported previously in HCLE and HCjE cells [10]. The finding in the present study where BCH was found to inhibit L-[3H]carnitine uptake, suggests that ATB0,+ may be involved in L-carnitine transport in HCLE and HCjE cells. The expression of this transporter was detected but at a much lower level relative to OCTN1 and OCTN2 (Figure 4).

Figure 4
Relative expression of OCTN1, OCTN2, and ATB0,+ in human ocular epithelial cells. Representative image of semi-quantitative RT PCR -amplified human OCTN1, OCTN2, ATB0,+, and ACTB products. In the image, Lanes 1,3,5,7 show HCLE product and Lanes 2,4,6,8 ...

The blocking effect of OCTN1 and OCTN2 antibody on the uptake of L-[3H]carnitine by HCLE and HCjE cells

As shown in Figure 5, the anti-OCTN2 antibody blocked L-[3H]carnitine uptake in both HCLE (p=0.004) and HCjE (p=0.019) cells. The anti-OCTN1 antibody, on the other hand, did not significantly block uptake when compared with the control group nor did it contribute to blocking in combination with OCTN2 (Figure 5).

Figure 5
Blocking effect of OCTN1 and/or OCTN2 antibody on the uptake of L-[3H]carnitine by HCLE or HCjE cells at 37 °C. HCLE or HCjE cells were pre-incubated for 60 min in uptake buffer containing OCTN1 (1:500) and/or OCTN2 (1:500) antibody at ...

Discussion

Carnitine transport has been extensively studied in a variety of human and animal tissues, such as kidney, skeletal muscle, heart, placenta, brain [20], mammary gland epithelia [11], liver [26], and rabbit conjunctiva [9]. However, little is known about the function of carnitine transporters present in ocular tissues including the corneal and conjunctival epithelia [10]. This present study provides further insights into the mechanism of carnitine transport in cultured human ocular epithelial cells, and the transporters specific for this process.

Our findings indicate that the uptake of L-[3H]carnitine in both HCLE and HCjE cells is saturable and Na+-dependent with the uptake profile for both cell lines comprising two distinct and significantly different components, suggesting the existence of both high and low affinity L-carnitine transport systems. The high affinity system Km, obtained in the present study for HCLE and HCjE cell lines (9.48 µM and 9.39 µM, respectively) is similar to that derived for the high affinity L-carnitine transporter, OCTN2, in various other tissues; for example, conditionally immortalized rat retinal capillary endothelial cells (29.0±13.8µM) [27], isolated rat kidney brush border membrane vesicles (17.4 µM) [28], LLC-PK1 cells (11.0 µM) [29], and CHO cells with functional expression of OCTN2 (8.01 µM) [30]. Our values are in good agreement with the range of 8.01–29 µM reported for the above studies performed at 37 °C, pH 7.4.

Metabolic inhibitors that uncouple oxidative phosphorylation (sodium azide and dinitrophenol) [26], as well as those that inhibit glycolytic ATP generation (iodoacetic acid) reduced the L-[3H]carnitine uptake, further indicating that L-carnitine is transported by an energy-dependent, active carrier-mediated transport system. The uptake activity was also found to be pH-dependent. Since changes in pH could affect the conformation of the transporter within the plasma membrane, this could have a direct effect on the transport of L-carnitine [26]. This pH-dependence might be ascribed to at least two underlying mechanisms, including activation by a proton gradient, or by the presence of a functionally optimal protonated form of the transporter [16]. The activity demonstrated here is similar to the activity of L-carnitine transport in the human placental brush-border membrane [15], but differs from that reported for cultured human hepatoma HLF cells, in which the uptake was highest at pH 7.4 [26]. This variation in optimal pH between different cell types warrants further investigation.

The involvement of the transporters, OCTN2 or ATB0,+, in the transport of carnitine was further confirmed by inhibition (substrate specific) studies. The concentration-dependent inhibition studies showed that carnitine transport activity was reduced by the carnitine analogs (L-carnitine, D-carnitine, acetyl-L-carnitine, and γ-butyrobetaine) and organic cationic compound (TEA). The inhibitory potencies of these compounds agree with those previously reported for the inhibition of OCTN2-mediated transport [31,32]. A recent study by Tachikawa and colleagues [33] found similar inhibition with L-carnitine and TEA in their studies across the inner blood-retinal barrier. They concluded that OCNT2 is most likely involved in L-carnitine transport. Similar inhibition was also observed in the OCTN2-transfected HEK cells [20]. Using polarized monolayers of HCLE and HCjE cells, we have previously demonstrated that the majority of carnitine was transported to the apical surface of the cells, consistent with the localization of OCTN2 found predominantly on apical membrane of the cells [10]. In agreement with the findings of others [20], our data here provide functional characteristic evidence of the OCTN2-actively mediated L-carnitine transport process for the human corneal and conjunctival epithelial cells. This may also offer further support for other reported findings where the uptake of L-carnitine into ocular tissues is observed [4,8,9].

ATB0,+, on the other hand, is a Na+- and Cl-- coupled transport system for neutral and cationic amino acids. It is a low-affinity transporter for L-carnitine and is sensitive to BCH at high concentrations (5–10 mM) [22]. In the present study, we also found that BCH (0.1 and 10 mM) inhibited the L-[3H]carnitine uptake in HCLE and HCjE cells with greater inhibition exhibited at higher concentrations. Further, the real-time PCR analysis detected a low level of ATB0,+ in these cells. These data suggest that ATB0,+ may also play a role in the L-carnitine transport process, as has been suggested previously [22,34]. In contrast to OCNT2, ATB0, + does not transport acetyl-carnitine, highlighting differential affinities of OCTN2 and ATB0,+ which may dictate independent physiologic roles [22].

OCTN1 is a pH-dependent organic cation transporter that transports L-carnitine in a Na+-dependent manner [17,18]. Rat intestinal OCTN1, however, reportedly interacts with L-carnitine with low affinity and in a Na+-independent manner [35]. Conversely, OCTN2 transports carnitine with high affinity in a Na+-dependent manner and transports organic cations in a Na+-independent manner [15,19]. The observed blocking of L-[3H]carnitine uptake by OCTN2-specific antibodies, but not with OCTN1-specific antibodies, further supports the hypothesis that OCTN2 plays a major role in the transport of carnitine in human ocular epithelial cells and constitutes the high affinity transport component. The contribution of both OCTN1 and ATB0,+ need to be further addressed to elucidate the nature of the low affinity kinetic component.

L-carnitine is present in considerable quantities in the tears of normal healthy eyes [7]. However, for dry eye patients, the tear carnitine level is reduced significantly [7]. Corrales et al. [2] have shown that L-carnitine can protect against stress activation of corneal epithelial cells in response to hyperosmolar stress. We also demonstrated that carnitine protects corneal epithelial cells from hyperosmolar solution induced damage [3]. Taken together these observations support the hypothesis that carnitine plays a crucial role in protecting ocular surfaces from hyperosmolarity-induced damage, thus contributing to the reduction of deleterious physiologic changes in dry eye. In addition, this present work provided evidence that carnitine can be actively transported to the ocular cells in a Na+-dependent manner, potentially extending the application of carnitine not only as a micronutrient but also as a beneficial compatible solute in topically administered ophthalmic formulations, such as artificial tears, to enhance cell survival under hypertonic conditions.

In conclusion, high- and low-affinity L-carnitine transport occurs in human HCLE and HCjE cells. Consistent with our previous demonstration of OCTN2 expression in these cells, the present work provides further evidence of an active high-affinity transport system for carnitine in the ocular epithelial cells that is Na+-, pH-, and energy-dependent with characteristics resembling OCTN2.

Acknowledgments

This work was supported in part by Allergan Inc. Irvine, CA. The authors wish to thank Professor Ilene Gipson’s laboratory (The Schepens Eye Research Institute, Boston, MA) for providing the HCLE and HCjE cell lines. The views presented represent those of the authors and not necessarily those of the funding bodies.

References

1. Pessotto P, Liberati R, Petrella O, Romanelli L, Calvani M, Peluso G. In experimental diabetes the decrease in the eye of lens carnitine levels is an early important and selective event. Exp Eye Res. 1997;64:195–201. [PubMed]
2. Corrales RM, Luo L, Chang EY, Pflugfelder SC. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea. 2008;27:574–9. [PubMed]
3. Garrett Q, Min-Hsuan Shih S, Simmons PA, Vehige J, Willcox M. Carnitine and the Potential Osmoprotectants Protect Corneal Epithelial Cells from Hyperosmolar Solution Induced Damage. ARVO Annual Meeting; 2010 May 2–6; Fort Lauderdale (FL).
4. Simmons P, Chang-Lin J, Chung Q, Vehige J, Carlisle-Wilcox C, Welty D. Selection of compatible solutes for inclusion in a lubricant eye drop. TFOS meeting 2007 September, 2007; Sicily, Italy.
5. Kerner J, Hoppel C. Genetic disorders of carnitine metabolism and their nutritional management. Annu Rev Nutr. 1998;18:179–206. [PubMed]
6. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta. 2000;1486:1–17. [PubMed]
7. Pescosolido N, Imperatrice B, Koverech A, Messano M. L-carnitine and short chain ester in tears from patients with dry eye. Optom Vis Sci. 2009;86:E132–8. [PubMed]
8. Simmons P, Chang-Lin J, Chung Q, Vehige J, Welty D. Effect of compatible solutes on transepithelial electrical resistance and uptake in primary rabbit corneal epithelial cell layers model. ARVO Annual Meeting; 2007 May 6–10; Fort Lauderdale (FL).
9. Ueda H, Horibe Y, Kim KJ, Lee VH. Functional characterization of organic cation drug transport in the pigmented rabbit conjunctiva. Invest Ophthalmol Vis Sci. 2000;41:870–6. [PubMed]
10. Garrett Q, Xu S, Simmons PA, Vehige J, Flanagan JL, Willcox MD. Expression and localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium. Invest Ophthalmol Vis Sci. 2008;49:4844–9. [PubMed]
11. Kwok B, Yamauchi A, Rajesan R, Chan L, Dhillon U, Gao W, Xu H, Wang B, Takahashi S, Semple J, Tamai I, Nezu J, Tsuji A, Harper P, Ito S. Carnitine/xenobiotics transporters in the human mammary gland epithelia, MCF12A. Am J Physiol Regul Integr Comp Physiol. 2006;290:R793–802. [PubMed]
12. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004;447:666–76. [PubMed]
13. Grube M, Meyer zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K, Rosskopf D, Eckel L, Bohm M, Jedlitschky G, Kroemer HK. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation. 2006;113:1114–22. [PubMed]
14. Grube M, Schwabedissen HM, Draber K, Prager D, Moritz KU, Linnemann K, Fusch C, Jedlitschky G, Kroemer HK. Expression, localization, and function of the carnitine transporter OCTN2 (slc22a5) in human placenta. Drug Metab Dispos. 2005;33:31–7. [PubMed]
15. Lahjouji K, Elimrani I, Lafond J, Leduc L, Qureshi IA, Mitchell GA. L–Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am J Physiol Cell Physiol. 2004;287:C263–9. [PubMed]
16. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999;289:768–73. [PubMed]
17. Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, Shimane M, Tsuji A. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem. 2000;275:40064–72. [PubMed]
18. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, Tsuji A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 1997;419:107–11. [PubMed]
19. Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, Wanner A. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol. 2007;36:53–60. [PMC free article] [PubMed]
20. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem. 1998;273:20378–82. [PubMed]
21. Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N, Goto A, Sakamoto A, Niwa T, Kanai Y, Anders MW, Endou H. Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem. 2002;277:36262–71. [PubMed]
22. Nakanishi T, Hatanaka T, Huang W, Prasad PD, Leibach FH, Ganapathy ME, Ganapathy V. Na+- and Cl–coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol. 2001;532:297–304. [PubMed]
23. Garrett Q, Simmons PA, Xu S, Vehige J, Zhao Z, Ehrmann K, Willcox M. Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2007;48:1559–67. [PubMed]
24. Gipson IK, Spurr-Michaud S, Argueso P, Tisdale A, Ng TF, Russo CL. Mucin gene expression in immortalized human corneal-limbal and conjunctival epithelial cell lines. Invest Ophthalmol Vis Sci. 2003;44:2496–506. [PubMed]
25. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001;59:358–66. [PubMed]
26. Yokogawa K, Miya K, Tamai I, Higashi Y, Nomura M, Miyamoto K, Tsuji A. Characteristics of L-carnitine transport in cultured human hepatoma HLF cells. J Pharm Pharmacol. 1999;51:935–40. [PubMed]
27. Tachikawa M, Takeda Y, Tomi M, Hosoya K. Involvement of OCTN2 in the transport of acetyl-L-carnitine across the inner blood-retinal barrier. Invest Ophthalmol Vis Sci. 2010;51:430–6. [PubMed]
28. Stieger B, O'Neill B, Krahenbuhl S. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem J. 1995;309:643–7. [PubMed]
29. Okamura N, Ohnishi S, Shimaoka H, Norikura R, Hasegawa H. Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid. Pharm Res. 2006;23:1729–35. [PubMed]
30. Ohnishi S, Okamura N, Sakamoto S, Hasegawa H, Norikura R, Kanaoka E, Takahashi K, Horie K, Sakamoto K, Baba T. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. Drug Metab Pharmacokinet. 2008;23:293–303. [PubMed]
31. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999;291:778–84. [PubMed]
32. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999;290:1482–92. [PubMed]
33. Tachikawa M, Takeda Y, Tomi M, Hosoya K. Involvement of OCTN2 in the Transport of Acetyl-L-Carnitine across the Inner Blood-Retinal Barrier. Invest Ophthalmol Vis Sci. 2010;51:430–6. [PubMed]
34. D'Argenio G, Calvani M, Casamassimi A, Petillo O, Margarucci S, Rienzo M, Peluso I, Calvani R, Ciccodicola A, Caporaso N, Peluso G. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes. FASEB J. 2006;20:2544–6. [PubMed]
35. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000;1466:315–27. [PubMed]

Articles from Molecular Vision are provided here courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China